Business · 02/05/2023Updated: 10/17/2026 · 1 min read
FDA Corrects Notice on Risk-Based Approach to Clinical Investigations Guidance
Summary
The FDA is correcting a notice that incorrectly listed an OMB control number for its final guidance on a risk-based approach to monitoring clinical investigations, which was published in the Federal Register on April 12, 2023.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →